Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Short term Debt (2021 - 2026)

Cardiol Therapeutics filings provide 2 years of Short term Debt readings, the most recent being $309342.3 for Q4 2022.

  • On a quarterly basis, Short term Debt fell 94.15% to $309342.3 in Q4 2022 year-over-year; TTM through Dec 2022 was $309342.3, a 94.15% decrease, with the full-year FY2022 number at $309342.3, down 94.15% from a year prior.
  • Short term Debt hit $309342.3 in Q4 2022 for Cardiol Therapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $5.3 million in Q4 2021 to a low of $309342.3 in Q4 2022.